[Email id of designated official for the purpose of grievance redressal]
UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 30TH JUNE, 2003 |
|||
---|---|---|---|
(RS. IN LACS) |
|||
PARTICULARS |
3 Months 30.06.2003 (UNAUDITED) |
3 Months 30.06.2002 (UNAUDITED) |
12 Months 31.03.2003 (UNAUDITED) |
INCOME FROM OPERATIONS | 4904.08 |
4464.51 |
17828.63 |
OTHER INCOME | 8.51 |
15.75 |
168.18 |
TOTAL INCOME | 4912.59 |
4480.26 |
17996.81 |
TOTAL EXPENDITURE | 4381.97 |
4062.00 |
16128.02 |
DECREASE IN STOCK IN TRADE | 25.46 |
84.96 |
-665.06 |
CONSUMPTION OF RAW MATERIAL | 3681.07 |
3283.95 |
14275.96 |
STAFF COST | 150.62 |
126.69 |
596.86 |
OTHER EXPENSES | 524.82 |
566.40 |
1920.26 |
INTEREST | 164.24 |
83.65 |
574.92 |
DEPRECIATION | 22.47 |
18.56 |
78.07 |
PROFIT BEFORE TAX | 343.91 |
316.05 |
1215.80 |
PROVISION FOR TAX | 25.79 |
23.70 |
91.19 |
PROVISION FOR DEFERRED TAX | 13.36 |
21.75 |
59.37 |
EXCESS PROVISION WRITTEN BACK INCOME TAX FOR THE PREV.YEAR | - |
- |
-2.60 |
NET PROFIT | 304.76 |
270.60 |
1067.85 |
PAID UP EQUITY CAPITAL | 439.50 |
439.50 |
439.50 |
RESERVES EXCLUDING REVALUATION RESERVES | - |
- |
- |
EPS | 6.93 |
6.16 |
24.30 |
NOTES: |
|||
1. During the quarter under review, the turnover and the net profit of the company has increased by 58.53% & 55.16% respectively as compared to the corresponding quarter of the previous year. 2. As per IMS April 2002 Report the Company is growing at a compounded annual growth rate of over 89%and is ranked among the top fastest growing companies of India. 3. During the Quarter Company received the DCGI approval for the marketing of the fastest growing Anti-Depressant Drug Citalopram in India. 4. The Company is exclusively in the Pharmaceutical business segment. 5. The above financial results were taken on record by the Board at its meeting held on 27th July, 2002. |
|||
By Order of the Board For Ind-Swift Limited |
|||
Dated: 31.07.2003 |
(Sanjeev Rai Mehta) |
||
Place: Chandigarh |
Managing Director |
||